相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Medicine, General & Internal
Christopher C. Butler et al.
Summary: This study aimed to determine the safety, effectiveness, and cost-effectiveness of molnupiravir in vaccinated high-risk patients in the community. The results showed that molnupiravir did not reduce hospital admissions or deaths associated with COVID-19 compared to usual care in this population.
Article
Pharmacology & Pharmacy
Laura Vangeel et al.
Summary: Remdesivir and its parent nucleoside, molnupiravir and its parent nucleoside, and the viral protease inhibitor nirmatrelvir have equipotent antiviral activity against the ancestral SARS-CoV2 strain and the variants of concern including Omicron.
ANTIVIRAL RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Article
Medicine, General & Internal
A. Jayk Bernal et al.
Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Emi Takashita et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
William A. Fischer et al.
Summary: In a clinical trial, the safety, tolerability, and antiviral efficacy of molnupiravir were evaluated in unvaccinated individuals with confirmed SARS-CoV-2 infection. The study found that participants receiving high-dose molnupiravir had a shorter time to viral RNA clearance and a lower detection rate of infectious virus. Molnupiravir was well tolerated across all doses.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Endocrinology & Metabolism
Awadhesh Kumar Singh et al.
Summary: Molnupiravir is an oral antiviral drug that has received emergency use authorization in the USA, UK, and India. Recent studies have shown that it can significantly reduce the risk of hospitalization or death in non-hospitalized COVID-19 patients. Molnupiravir is comparatively cheaper than other agents and can be an effective option for treating COVID-19, but it needs to be used within 5 days of symptom onset.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2022)
Review
Medicine, General & Internal
Md Mohsin et al.
Summary: Omicron, a new variant of Covid-19, spreads at an unprecedented speed and has the ability to evade immunity. However, infections caused by Omicron are less severe compared to Delta and other variants. Vaccines and booster shots remain effective in protecting against severe Covid-19 infections.
Article
Cell Biology
Liu Cao et al.
Summary: ATV006, an orally bioavailable antiviral drug candidate, showed potent efficacy against various SARS-CoV-2 variants and reduced viral loads and lung damage in mouse models.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Yinzhong Shen et al.
Summary: VV116 is a safe and effective oral antiviral drug that shows better performance in the early onset of omicron infection.
EMERGING MICROBES & INFECTIONS
(2022)
Review
Immunology
Yifei Guo et al.
Summary: The Omicron variant of SARS-CoV-2, designated as a variant of concern by WHO, has rapidly spread worldwide, possibly due to mutations in its spike protein that reduce the protective effects of neutralizing antibodies. However, compared to previous variants, the Omicron variant has lower hospitalization and mortality rates, and the effectiveness of vaccination and antiviral drugs has not been significantly affected. Both Fc-mediated and T-cell immunity functions have been well retained.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Fahadul Islam et al.
Summary: This article discusses the mutation of the new coronavirus Omicron variant, its potential impact on vaccines and antibody therapy, raising international concerns about its transmission, detection, and vaccine efficacy.
ANNALS OF MEDICINE AND SURGERY
(2022)
Review
Oncology
Ziwen Qin et al.
Summary: This review summarizes the epidemiological investigation and etiological analysis of the original strain and its variants of the COVID-19 virus, including their genomic, epidemiological, and pathological characteristics, as well as progress in diagnosis and treatment. It also discusses the prevention and control measures used during the current Omicron pandemic.
MOLECULAR MEDICINE REPORTS
(2022)
Article
Pharmacology & Pharmacy
Rongrong Zou et al.
Summary: This study evaluated the antiviral efficacy and safety of molnupiravir in patients infected with the SARS-CoV-2 Omicron variant. The results showed that molnupiravir significantly accelerated viral RNA clearance and had a good safety profile.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Kavya Atluri et al.
Summary: This review discusses effective therapeutic strategies for COVID-19 and attempts to contextualize their efficacy with emerging variants. However, vaccines are not included in this review.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Infectious Diseases
Saye H. Khoo et al.
Summary: This study aimed to evaluate the efficacy and safety of molnupiravir in patients with COVID-19 who have been vaccinated or unvaccinated. The results suggest that molnupiravir might have antiviral activity against SARS-CoV-2 infection.
LANCET INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Carlos K. H. Wong et al.
Summary: This retrospective cohort study evaluated the clinical and virological outcomes associated with molnupiravir or nirmatrelvir-ritonavir use in hospitalised patients with mild-to-moderate COVID-19. The results showed that recipients of oral antivirals had a lower risk of all-cause mortality, disease progression, need for oxygen therapy, and a shorter time to reaching a low viral burden. The study supports the early use of oral antivirals in this population of patients.
LANCET INFECTIOUS DISEASES
(2022)
Article
Pharmacology & Pharmacy
Robert Flisiak et al.
Summary: This study assessed the effectiveness of molnupiravir in hospitalized COVID-19 patients during the Omicron variant dominance, finding a significant reduction in mortality with MOL treatment, particularly in patients over 80 years of age.
PHARMACOLOGICAL REPORTS
(2022)
Article
Microbiology
Michela Pontolillo et al.
Summary: This study reports the experience of using molnupiravir in the treatment of COVID-19 patients. The results show that participants demonstrated early clinical improvement, no need for hospitalization, and a low rate of adverse events after receiving the treatment.
Article
Infectious Diseases
Tommaso Lupia et al.
Summary: This study retrospectively analyzed the use of molnupiravir therapy in patients with underlying diseases and COVID-19 infection. The findings suggest that molnupiravir treatment is safe and well tolerated in this population, but its efficacy remains controversial.
Article
Infectious Diseases
Yayun Liu et al.
Summary: The efficacy of MLN in older adults diagnosed with Omicron BA.2 was investigated. MLN use was associated with faster achievement of undetectable viral load and shorter hospital stay compared to non-MLN use in elderly COVID-19 patients.
INFECTIOUS DISEASES AND THERAPY
(2022)
Article
Chemistry, Medicinal
Anca Streinu-Cercel et al.
Summary: During the current pandemic, the gap between fundamental research and clinical practice has been narrowing. A retrospective analysis of outpatient treatment with molnupiravir in Bucharest, Romania, showed that the drug was well tolerated and associated with a favorable outcome in COVID-19 patients.
Article
Medicine, Research & Experimental
Yasuhito Suzuki et al.
Summary: This real-world study demonstrates that molnupiravir contributes to the prevention of deterioration in COVID-19 patients after hospitalization during the Omicron variant phase.
CLINICAL AND EXPERIMENTAL MEDICINE
(2022)
Article
Infectious Diseases
Zarir F. Udwadia et al.
Summary: The study aimed to assess the efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19. Results showed a significant improvement in time to clinical cure with favipiravir, although there was no statistically significant difference in viral shedding cessation time.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
